TWI721946B - 色瑞替尼調配物 - Google Patents

色瑞替尼調配物 Download PDF

Info

Publication number
TWI721946B
TWI721946B TW104117053A TW104117053A TWI721946B TW I721946 B TWI721946 B TW I721946B TW 104117053 A TW104117053 A TW 104117053A TW 104117053 A TW104117053 A TW 104117053A TW I721946 B TWI721946 B TW I721946B
Authority
TW
Taiwan
Prior art keywords
pharmaceutical composition
ceritinib
tablet
weight percent
lozenge
Prior art date
Application number
TW104117053A
Other languages
English (en)
Chinese (zh)
Other versions
TW201613580A (en
Inventor
賽巴斯汀 布雷優樂斯
西門 恩斯林
Original Assignee
瑞士商諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53298568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI721946(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 瑞士商諾華公司 filed Critical 瑞士商諾華公司
Publication of TW201613580A publication Critical patent/TW201613580A/zh
Application granted granted Critical
Publication of TWI721946B publication Critical patent/TWI721946B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
TW104117053A 2014-05-29 2015-05-27 色瑞替尼調配物 TWI721946B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462004359P 2014-05-29 2014-05-29
US62/004,359 2014-05-29

Publications (2)

Publication Number Publication Date
TW201613580A TW201613580A (en) 2016-04-16
TWI721946B true TWI721946B (zh) 2021-03-21

Family

ID=53298568

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104117053A TWI721946B (zh) 2014-05-29 2015-05-27 色瑞替尼調配物

Country Status (27)

Country Link
US (4) US20170112834A1 (OSRAM)
EP (1) EP3148513B1 (OSRAM)
JP (3) JP6679578B2 (OSRAM)
KR (1) KR20170008239A (OSRAM)
CN (1) CN106456640B (OSRAM)
AR (1) AR100625A1 (OSRAM)
AU (3) AU2015265470A1 (OSRAM)
BR (1) BR112016027580A8 (OSRAM)
CA (1) CA2948291A1 (OSRAM)
CL (1) CL2016003047A1 (OSRAM)
DK (1) DK3148513T3 (OSRAM)
EA (1) EA036922B1 (OSRAM)
EC (1) ECSP16096826A (OSRAM)
ES (1) ES2792574T3 (OSRAM)
HU (1) HUE048950T2 (OSRAM)
IL (1) IL248835B (OSRAM)
MX (1) MX373624B (OSRAM)
PE (1) PE20170313A1 (OSRAM)
PH (1) PH12016502272A1 (OSRAM)
PL (1) PL3148513T3 (OSRAM)
PT (1) PT3148513T (OSRAM)
SG (1) SG11201609208UA (OSRAM)
SI (1) SI3148513T1 (OSRAM)
TN (1) TN2016000484A1 (OSRAM)
TW (1) TWI721946B (OSRAM)
UY (1) UY36140A (OSRAM)
WO (1) WO2015181739A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015265470A1 (en) 2014-05-29 2016-11-24 Novartis Ag Ceritinib formulation
CN106176752B (zh) * 2015-05-07 2020-06-23 石药集团中奇制药技术（石家庄）有限公司 色瑞替尼药物组合物
CN109381440A (zh) * 2018-11-15 2019-02-26 威海贯标信息科技有限公司 一种艾乐替尼组合物
CN113244236B (zh) * 2021-06-01 2023-02-03 上海市第一人民医院 色瑞替尼在制备治疗甲状腺相关眼病的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008073687A2 (en) * 2006-12-08 2008-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3632778A (en) * 1970-06-10 1972-01-04 Hoffmann La Roche Tablets containing l-dopa
PE20071315A1 (es) * 2006-03-06 2008-02-14 Wyeth Corp Formulaciones de compuestos derivados de fenilo y procesos de preparacion para tabletas que contienen dichos compuestos
US20090239920A1 (en) 2006-11-21 2009-09-24 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080175901A1 (en) 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
BRPI0722383A2 (pt) * 2006-12-08 2012-06-05 Irm Llc compostos inibidores de proteìna quinase, composições contendo os mesmos bem como seus usos
EP2090297A1 (en) 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
SI2334202T1 (sl) 2008-09-04 2012-04-30 Cargill Inc Tabletiranje eritritola
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
BR112012003631A2 (pt) 2009-08-18 2015-09-01 Gargill Inc "produção de comprimidos de eritritol e isomalte."
JP5596799B2 (ja) 2010-05-11 2014-09-24 田辺三菱製薬株式会社 カナグリフロジン含有錠剤
JP2013536694A (ja) 2010-09-07 2013-09-26 カーギル インコーポレイテッド 凝固糖アルコール混合物
AU2015265470A1 (en) 2014-05-29 2016-11-24 Novartis Ag Ceritinib formulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008073687A2 (en) * 2006-12-08 2008-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Journal of Chemical and Pharmaceutical Research, 2013, 5(11):617-625
N Anjali Devi et al. IRJP 2012, 3 (9) ,185-193
N Anjali Devi et al. IRJP 2012, 3 (9) ,185-193 Journal of Chemical and Pharmaceutical Research, 2013, 5(11):617-625 *

Also Published As

Publication number Publication date
US20200009141A1 (en) 2020-01-09
AU2018203007B2 (en) 2019-07-18
CN106456640B (zh) 2021-05-14
US11000523B2 (en) 2021-05-11
JP2022078236A (ja) 2022-05-24
JP2020114834A (ja) 2020-07-30
IL248835B (en) 2020-05-31
TW201613580A (en) 2016-04-16
ECSP16096826A (es) 2018-04-30
PT3148513T (pt) 2020-05-27
MX373624B (es) 2020-05-22
CL2016003047A1 (es) 2017-04-07
BR112016027580A8 (pt) 2021-06-29
DK3148513T3 (da) 2020-05-25
US20210154194A1 (en) 2021-05-27
HUE048950T2 (hu) 2020-09-28
JP2017520619A (ja) 2017-07-27
PE20170313A1 (es) 2017-04-18
WO2015181739A1 (en) 2015-12-03
EP3148513A1 (en) 2017-04-05
EA201692310A1 (ru) 2017-04-28
AU2018203007A1 (en) 2018-05-17
PL3148513T3 (pl) 2020-08-24
AR100625A1 (es) 2016-10-19
EA036922B1 (ru) 2021-01-15
AU2019232937B2 (en) 2020-10-15
KR20170008239A (ko) 2017-01-23
BR112016027580A2 (pt) 2017-08-15
MX2016015736A (es) 2017-03-16
AU2015265470A1 (en) 2016-11-24
US20190022095A1 (en) 2019-01-24
SI3148513T1 (sl) 2020-07-31
ES2792574T3 (es) 2020-11-11
US12357630B2 (en) 2025-07-15
UY36140A (es) 2016-01-08
SG11201609208UA (en) 2016-12-29
JP7084955B2 (ja) 2022-06-15
PH12016502272A1 (en) 2017-02-06
US20170112834A1 (en) 2017-04-27
CN106456640A (zh) 2017-02-22
TN2016000484A1 (en) 2018-04-04
CA2948291A1 (en) 2015-12-03
IL248835A0 (en) 2017-01-31
EP3148513B1 (en) 2020-02-26
AU2019232937A1 (en) 2019-10-10
JP6679578B2 (ja) 2020-04-15

Similar Documents

Publication Publication Date Title
CN106943355B (zh) 药物组合物
US12357630B2 (en) Ceritinib formulation
CN119112820A (zh) 来那度胺的口服用片剂组合物
WO2006123678A1 (ja) ドロキシドパを含有する安定な錠剤
RS66060B1 (sr) Sastav koji sadrži ramipril i indapamid
Ofori-Kwakye et al. Formulation and quality evaluation of two conventional release tablet formulations
CN103638000A (zh) 含达比加群酯的分散制剂
US20160022661A1 (en) Dosage Form Comprising Crizotinib
CN103768068A (zh) 一种波生坦药物组合物
JP2021506750A (ja) アカルボースおよびメトホルミンの固定用量組合せ錠剤製剤およびその製造方法
CN112512511B (zh) 具有cdc7抑制剂的药物组合物
HK1229715B (en) Ceritinib formulation
HK1229715A1 (en) Ceritinib formulation
CN108236609B (zh) 一种gpr40激动剂药物组合物及其制备方法
TW202500156A (zh) 包含具有ｇ１２ｃ突變的ｋ－ｒａｓ蛋白之抑制劑的固體調配物及製備方法
TW202339723A (zh) 一種固體藥物組合物
WO2023036980A1 (en) Pharmaceutical composition of bempedoic acid
CA2927437A1 (en) Pharmaceutical dosage forms containing sodium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1h-1,2,3-triazol-1-yl)-1h-pyrazol-5-olate
EA041427B1 (ru) Фармацевтические лекарственные формы
CN104013587A (zh) 即释片形式的包含1h-喹唑啉-2,4-二酮ampa受体拮抗剂的制剂及其制备方法

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees